Detalhe da pesquisa
1.
Bayesian adaptive design for clinical trials in Duchenne muscular dystrophy.
Stat Med
; 40(19): 4167-4184, 2021 08 30.
Artigo
Inglês
| MEDLINE | ID: mdl-33960507
2.
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.
Alzheimers Dement
; 16(1): 131-143, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31668596
3.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Lancet
; 380(9856): 1829-39, 2012 Nov 24.
Artigo
Inglês
| MEDLINE | ID: mdl-23122650
4.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Lancet
; 380(9856): 1819-28, 2012 Nov 24.
Artigo
Inglês
| MEDLINE | ID: mdl-23122652
5.
Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease.
Neurol Genet
; 6(3): e430, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32548276
6.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
N Engl J Med
; 354(9): 899-910, 2006 Mar 02.
Artigo
Inglês
| MEDLINE | ID: mdl-16510744
7.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
N Engl J Med
; 354(9): 911-23, 2006 Mar 02.
Artigo
Inglês
| MEDLINE | ID: mdl-16510745
8.
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Ann Neurol
; 62(4): 335-46, 2007 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-17696126
9.
Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.
Neurol Neuroimmunol Neuroinflamm
; 4(5): e390, 2017 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-28828394
10.
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
Neurology
; 89(11): 1107-1116, 2017 Sep 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28835401
11.
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
Neurology
; 89(11): 1117-1126, 2017 Sep 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28835403
12.
More on melanoma with transdifferentiation.
N Engl J Med
; 359(1): 99; author reply 99-100, 2008 Jul 03.
Artigo
Inglês
| MEDLINE | ID: mdl-18596284
13.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Neurology
; 87(19): 1985-1992, 2016 Nov 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27733571
14.
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon ß-1a in MS.
Neurology
; 87(14): 1464-1472, 2016 Oct 04.
Artigo
Inglês
| MEDLINE | ID: mdl-27590291
15.
Natalizumab and central nervous system lymphoma: no clear association.
Ann Neurol
; 66(3): 261-2, 2009 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-19798645
16.
Diffusion-weighted magnetic resonance imaging abnormalities in Bartonella encephalopathy.
J Neuroimaging
; 13(1): 79-82, 2003 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-12593136
17.
Natalizumab and progressive multifocal leukoencephalopathy.
N Engl J Med
; 353(4): 432-3, 2005 Jul 28.
Artigo
Inglês
| MEDLINE | ID: mdl-15947083
18.
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.
J Interferon Cytokine Res
; 30(10): 777-85, 2010 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-20836711
19.
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
J Neurol Sci
; 292(1-2): 28-35, 2010 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-20236661
20.
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
J Neurol
; 256(3): 405-15, 2009 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-19308305